18^th Nanotechnology and Nanomedicine Congress

Nanomedicine seeks to deliver a valuable set of research tools and clinically useful devices in the near future. The National Nanotechnology Initiative expects new commercial applications in the pharmaceutical industry that may include advanced drug delivery systems, new therapies, and in vivo imaging. Nanomedicine research is receiving funding from the US National Institutes of Health Common Fund program, supporting four nanomedicine development centers. Nanomedicine sales reached $16 billion in 2015, with a minimum of $3.8 billion in nanotechnology R&D being invested every year. Global funding for emerging nanotechnology increased by 45% per year in recent years, with product sales exceeding $1 trillion in 2013. As the nanomedicine industry continues to grow, it is expected to have a significant impact on the economy.

A nanoparticle or ultrafine particle is usually defined as a particle of matter that is between 1 and 100 nanometers (nm) in diameter. The term is sometimes used for larger particles, up to 500 nm, or fibers and tubes that are less than 100 nm in only two directions. At the lowest range, metal particles smaller than 1 nm are usually called atom clusters instead. Nanoparticles are usually distinguished from micro particles (1-1000 µm), "fine particles" (sized between 100 and 2500 nm), and "coarse particles" (ranging from 2500 to 10,000 nm), because their smaller size drives very different physical or chemical properties, like colloidal properties and ultrafast optical effects or electric properties.

Development of a current medication atom from a customary structure to a novel conveyance framework can essentially improve its presentation as far as patient consistence, security and adequacy. As a Novel Drug Delivery System a current medication particle can get another life. A fittingly planned Novel Drug Delivery System can be a meaningful step forward for tackling the issues related towards the arrival of the medication at explicit site with explicit rate. The requirement for conveying medications to patients productively and with less symptoms has incited pharmaceutical organizations to participate in the advancement of new medication conveyance framework. Controlling the pharmacokinetics, pharmacodynamics, vague lethality, immunogenicity, bio acknowledgment, and viability of medications were produced. These new methodologies, frequently called drug delivery system (DDS), depend on interdisciplinary methodologies that join polymer science, pharmaceutics, bio conjugate science, and atomic science.

The interdisciplinary field of materials science, also commonly termed materials science and engineering, covers the design and discovery of new materials, particularly solids. The intellectual origins of materials science stem from the Age of Enlightenment, when researchers began to use analytical thinking from chemistry, physics, and engineering to understand ancient, phenomenological observations in metallurgy and mineralogy. Materials science still incorporates elements of physics, chemistry, and engineering. As such, the field was long considered by academic institutions as a sub-field of these related fields. Beginning in the 1940s, materials science began to be more widely recognized as a specific and distinct field of science and engineering, and major technical universities around the world created dedicated schools for its study.

Nanorobotics is the technology that is used to create machines whose sizes are in nanometer. Mainly Nano robots are of high significance in the research and development phase. The main purpose of Nano robots is to carry out a specific task redundantly and with precision at nanoscale dimensions. Nano robots are used in medical field to destroy cancer cells and in the Field of Hematology, ophthalmology. Nano robots will also have useful applications for biohazard defense, including improving the response to epidemic disease. Nanorobotics may also reduce contamination and provide successful screening for quarantine. In the event of an influenza epidemic for example, increased concentrations of alpha-NAGA enzyme in the blood stream could be used as a biomarker for the influenza infection.